Harvard's Gregory Verdine has big ambitions for his miniprotein 'braces' — and now $107M to guide them to the clinic

Nicole DeFeudis

Editor

Harvard scientist Gregory Verdine’s mission has always been clear: drug the undruggable. He’s now one step closer, with $107 million in the bank to bring …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Harvard's Gregory Verdine has big ambitions for his miniprotein 'braces' — and now $107M to guide them to the clinic

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Har­vard's Gre­go­ry Ver­dine has big am­bi­tions for his minipro­tein 'braces' — and now $107M to guide them to the clin­ic

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Harvard's Gregory Verdine has big ambitions for his miniprotein 'braces' — and now $107M to guide them to the clinic